(Globes) Israeli blood analysis startup PixCell has been awarded a 2.5 million euro grant by the European Commission to accelerate commercialization of its HemoScreen. The product is a portable, easy-to-use, blood analyzer that can be operated by anyone. It performs the most common blood test - a complete blood count - within 5 minutes, enabling physicians to diagnose and treat their patients during a single visit. HemoScreen's performance has been comprehensively validated in 3 clinical studies in the U.S. in which operators without any training have tested thousands of blood samples, showing excellent correlation to high-end lab analyzers. The product has EU CE approval and is expected to be FDA cleared during 2018.
2018-03-16 00:00:00Full ArticleBACK Visit the Daily Alert Archive